

# Neil M Walker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2296961/publications.pdf>

Version: 2024-02-01

16  
papers

1,342  
citations

759055

12  
h-index

940416

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

3223  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. <i>Nature Genetics</i> , 2015, 47, 381-386.   | 9.4 | 589       |
| 2  | Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. <i>Nature Genetics</i> , 2009, 41, 1011-1015.   | 9.4 | 249       |
| 3  | Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. <i>Nature Genetics</i> , 2015, 47, 839-846.   | 9.4 | 128       |
| 4  | Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. <i>PLoS Medicine</i> , 2016, 13, e1002139.   | 3.9 | 117       |
| 5  | Dissection of a Complex Disease Susceptibility Region Using a Bayesian Stochastic Search Approach to Fine Mapping. <i>PLoS Genetics</i> , 2015, 11, e1005272.  | 1.5 | 55        |
| 6  | Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. <i>JCI Insight</i> , 2017, 2, .  | 2.3 | 46        |
| 7  | Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. <i>BMJ Open</i> , 2014, 4, e005559-e005559.  | 0.8 | 33        |
| 8  | The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. <i>JCI Insight</i> , 2018, 3, .  | 2.3 | 29        |
| 9  | Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. <i>BMJ Open</i> , 2015, 5, e009799.  | 0.8 | 20        |
| 10 | Detection and correction of artefacts in estimation of rare copy number variants and analysis of rare deletions in type 1 diabetes. <i>Human Molecular Genetics</i> , 2015, 24, 1774-1790.   | 1.4 | 20        |
| 11 | A Genome-Wide Assessment of the Role of Untagged Copy Number Variants in Type 1 Diabetes. <i>PLoS Genetics</i> , 2014, 10, e1004367.   | 1.5 | 17        |
| 12 | Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. <i>Wellcome Open Research</i> , 2017, 2, 28.   | 0.9 | 14        |
| 13 | Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). <i>Trials</i> , 2015, 16, 86. | 0.7 | 9         |
| 14 | Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. <i>IScience</i> , 2022, 25, 103971.  | 1.9 | 7         |
| 15 | Returning findings within longitudinal cohort studies: the 1958 birth cohort as an exemplar. <i>Emerging Themes in Epidemiology</i> , 2014, 11, 10.  | 1.2 | 3         |
| 16 | All or Nothing: The False Promise of Anonymity. <i>Data Science Journal</i> , 2017, 16, .  | 0.6 | 1         |